Spruce Biosciences discontinues tildacerfont CAH program after Phase 2b miss

SPRUCE BIOSCIENCES, INC.

Phase 2b CAHmelia-204 missed primary endpoint: placebo-adjusted GC dose reduction of 0.7mg HCe (p=0.7).
98% compliance; no serious adverse events reported in CAHmelia-204.
Phase 2 CAHptain-205 showed trend of larger A4 reductions at higher BID doses; no drug-related SAEs.
Company discontinuing both trials, winding down tildacerfont investment, and evaluating strategic options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.